Search the Newsreel

Jupiter Neurosciences Inc (JUNS) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for Jupiter Neurosciences Inc (JUNS), indicating that no earnings forecast score is currently available, while the industry average is 8.10. Based on one analyst, the stock has a "Buy" rating with a target price of 25.000, representing 0.00% …

Jupiter Neurosciences, Inc. (JUNS) Stock Price, News, Quote & History

Jupiter Neurosciences, Inc. (JUNS) stock was trading at $5.30, down 5.90%, as of 1:45:04 p.m. EDT. The company announced a 1-for-75 reverse stock split effective August 7, 2026. Jupiter Neurosciences is a clinical-stage pharmaceutical company focused on developing therapeutics for central nervous system disorders …

Form 8K Jupiter Neurosciences Inc For: 6 August By Investing.com

This article reports on a Form 8K filing by Jupiter Neurosciences Inc. for August 6th. The content is very brief, mainly consisting of the headline and a reference to Reuters, indicating it's an announcement of the filing rather than an analysis of its contents. …

Jupiter Neurosciences grants 472,222 director options | JUNS Insider Trading

Jupiter Neurosciences (JUNS) has granted 472,222 stock options to director Andrew Jon Cutler under its 2025 Equity Incentive Plan. This grant, with an exercise price of $0.0900 per share, is in lieu of cash compensation for his board service. The options vest with 25% …

Jupiter Neurosciences executes 1-for-75 reverse stock split By Investing.com

Jupiter Neurosciences, Inc. (NASDAQ:JUNS) announced a 1-for-75 reverse stock split, approved by its board of directors and stockholders. This action is intended to increase the per share trading price to regain compliance with Nasdaq's minimum bid price requirement. The reverse split will reduce outstanding …

Kaskela Law Firm Announces Stockholder Investigation of Jupiter Neurosciences, Inc. (NASDAQ:JUNS) and Encourages Long-Term JUNS Investors to Contact the Firm

Kaskela Law LLC has initiated an investigation into Jupiter Neurosciences, Inc. (NASDAQ:JUNS) on behalf of its shareholders. The firm is looking into whether Jupiter and its officers/directors violated securities laws or breached fiduciary duties. Long-term JUNS investors are encouraged to contact Kaskela Law LLC …

Jupiter Neurosciences expands into psychedelics with $100m deal

Jupiter Neurosciences has acquired exclusive US rights to ALA-002, a clinical-stage psychedelic therapy candidate, for up to $100 million, marking its expansion into neuropsychiatric disorders. This move adds a second clinical program to Jupiter's portfolio, alongside therapies for Parkinson's disease, and signals a broader …

Jupiter Neurosciences (JUNS) Stock Forecast & Analyst Ratings

This article provides a stock forecast and analyst ratings for Jupiter Neurosciences (JUNS). It likely covers aspects such as price targets, current recommendations from analysts, and potential future performance. Investors can use this information to inform their decisions regarding the stock.

JUNS|Jupiter Neurosciences Inc|Price:0.099|Chg%:-0.000

This article provides a comprehensive stock analysis of Jupiter Neurosciences Inc (JUNS) by TradingKey. It highlights the company's healthy fundamentals, high growth potential, and current fair valuation. Despite recent weak stock market performance, the company shows strong technicals and has a high institutional ownership.

Jupiter Neurosciences (Nasdaq: JUNS) sells 11.47M shares under SEPA

Jupiter Neurosciences, Inc. issued and sold 11.47 million shares of common stock to YA II PN, Ltd. (Yorkville) between May 14, 2026, and July 24, 2026, under a Standby Equity Purchase Agreement (SEPA), generating approximately $3.6 million in gross proceeds. The company's reliance on …

Jupiter Neurosciences Inc (JUNS) Dividends & Stock Splits: Historical Payouts and Event Timeline

Jupiter Neurosciences Inc (JUNS) has not distributed any dividends over the past five years. The article provides current trading information for JUNS, showing a stock price of $0.114 USD, down 6.03%, with a market capitalization of $4.13 million. The company's dividend history section currently …

Jupiter Neurosciences Inc (JUNS) Cash Flow

This article provides the quarterly and annual cash flow statements for Jupiter Neurosciences Inc (JUNS), allowing users to evaluate the company's financial health. It details operating, investing, and financing cash flows, along with related metrics and definitions. The data shows changes in cash flow …

Jupiter Neurosciences, Inc. Files Form 8-K: Key Details on Nasdaq Listing, Address, and Corporate Status

Jupiter Neurosciences, Inc. (NASDAQ: JUNS) announced the results of its 2026 Annual Meeting, where shareholders approved all director nominees, ratified the independent auditor, and increased shares for the equity incentive plan. Critically, shareholders also approved a potential reverse stock split (1-for-10 to 1-for-100) to …

Jupiter Neurosciences (NASDAQ: JUNS) details Yorkville SEPA terms

Jupiter Neurosciences (JUNS) held its 2026 Annual Meeting, where stockholders approved the election of directors, ratified Cherry Bekaert LLC as independent accountants, amended the 2025 Equity Incentive Plan, and approved a reverse stock split. The company also detailed its Standby Equity Purchase Agreement (SEPA) …

Jupiter Neurosciences Inc (JUNS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article from TradingKey concerns Jupiter Neurosciences Inc (JUNS) and its revenue breakdown by business segments and regional contributions. However, the article states that relevant data for these breakdowns have not been disclosed by the company yet. It provides basic stock information for JUNS, …

TradingKey

This article provides a detailed balance sheet analysis for Jupiter Neurosciences Inc (JUNS), presenting both quarterly and annual financial metrics. It covers various asset, liability, and equity categories, allowing investors to evaluate the company's financial health, liquidity, and leverage. The financial data highlights changes …

Jupiter Neurosciences Inc (JUNS) Valuation: PE, PB & Fair Value Analysis

Psychedelic Therapy Meets M&A: Fireside Chat with Jupiter Neurosciences CEO Christer Rosén & President Alison Silva

IPO Edge hosted a fireside chat with Jupiter Neurosciences, Inc. CEO Christer Rosén and President Alison Silva to discuss the company's recent acquisition of exclusive U.S. rights to ALA-002, a patented MDMA formulation, valued at up to $100 million. This deal transforms Jupiter into …

CNS drug specialist Jupiter Neuro signs MDMA deal with PharmAla Biotech

Jupiter Neurosciences Inc. has secured exclusive U.S. rights to Pharmala Biotech's ALA-002, an MDMA formulation for neuropsychiatric conditions, in a deal valued up to US$100 million. This agreement expands Jupiter's focus from neurodegeneration to also include neuropsychiatric disorders, creating a dual clinical-stage pipeline. The …

Jupiter Neurosciences acquires US rights to ALA-002 in deal worth up to $100M

Jupiter Neurosciences has acquired the U.S. rights to ALA-002, a drug developed by Saneron CCEL Therapeutics for neurological and neuro-ophthalmic disorders, in a deal potentially worth up to $100 million. The agreement includes an upfront payment, milestone payments, and royalties on future sales. This …

Jupiter Neurosciences licenses MDMA drug ALA-002

Jupiter Neurosciences has licensed exclusive US rights to PharmAla Biotech Holdings' MDMA drug ALA-002, intended for neuropsychiatric disorders like PTSD and anxiety. The deal includes an upfront payment of $3.3 million and potential milestones up to $20 million upon FDA approval. This agreement signifies …

Jupiter Neurosciences (NASDAQ: JUNS) Signs Definitive Agreement for Exclusive U.S. Rights to ALA-002

Jupiter Neurosciences (NASDAQ: JUNS) has signed a definitive license agreement with PharmAla Biotech Holdings Inc. for perpetual exclusive U.S. rights to ALA-002, a patented, non-racemic MDMA formulation valued at up to $100 million. This acquisition expands Jupiter into a dual clinical-stage CNS company, adding …

Jupiter Neurosciences Enters License Agreement for Exclusive U.S. Rights to ALA-002, Expanding CNS Pipeline to Two Clinical-Stage Programs

Jupiter Neurosciences has secured exclusive U.S. rights to ALA-002, a patented MDMA formulation designated as a Novel Chemical Entity by the FDA, through a license agreement with PharmAla Biotech Holdings Inc. This deal, valued at up to $100 million, expands Jupiter's central nervous system …

Junshi Biosciences Announces Acceptance of the Supplemental Application for Toripalimab plus Chemotherapy as Perioperative Treatment for Resectable Stage Ⅱ-Ⅲ NSCLC

Junshi Biosciences SHANGHAI, July 21, 2026 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that the supplemental application for toripalimab in combination …

PharmAla Biotech Executes Definitive License Agreement Granting Jupiter Neurosciences Exclusive U.S. Rights to ALA-002

PharmAla Biotech Holdings Inc. has announced a definitive license agreement with Jupiter Neurosciences, granting Jupiter exclusive, perpetual U.S. rights to develop, manufacture, and commercialize ALA-002, PharmAla's lead drug candidate. The deal is valued at up to approximately US$100 million, including an upfront payment, milestone …

Jupiter enters psychedelics space with $100M deal for MDMA drug

Jupiter Neurosciences has acquired the U.S. rights to PharmAla Biotech's MDMA drug, ALA-002, for neuropsychiatric disorders, including PTSD. The deal includes an upfront payment of $3.3 million, with potential milestone payments and royalties totaling up to $100 million if the drug reaches Phase 3 …

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

This article identifies 12 healthcare stocks that are experiencing significant movement in pre-market trading on Tuesday. It lists both gainers, such as Jupiter Neurosciences and Imunon, and losers, including Zhengye Biotechnology and Lisata Therapeutics, along with their respective percentage changes and market capitalizations. The …

Jupiter Neurosciences Signs ALA-002 License Agreement Worth Up to $100 Million (NASDAQ:JUNS)

Jupiter Neurosciences (NASDAQ:JUNS) has signed an exclusive U.S. licensing agreement with PharmAla Biotech Holdings for ALA-002, a clinical-stage psychedelic therapeutic candidate, valued at up to $100 million. This deal transforms Jupiter into a dual clinical-stage CNS company, expanding its pipeline beyond its Parkinson's disease …

Jupiter Neurosciences Inc. (JUNS) Q4 2025 Earnings: EPS Beat Amid Pre-Revenue Phase; Stock Slips - EPS Growth Rate

JUNS Q4 2025 Earnings: Wider-Than-Expected Loss Narrows on Cost Control, Stock Rises - CFO Commentary Report

Jupiter Neurosciences earnings missed, revenue fell short of estimates

JUPITER NEUROSCIENCES, INC. 1Q 2026: Revenue $18.65K, Net loss $(2.06M) — 10-Q Summary

JUPITER NEUROSCIENCES (JUNS) Stock Price, News & Analysis